Literature DB >> 19251581

Anticardiolipin antibodies in patients with type 2 diabetes mellitus.

José María Calvo-Romero1, Esther María Lima-Rodríguez.   

Abstract

BACKGROUND: There is controversy about an increased prevalence of antiphospholipid antibodies in diabetic patients. The possible implications are little known.
METHODS: We prospectively studied all consecutive outpatients with type 2 diabetes mellitus (DM) attended to in an Internal Medicine office. IgM and IgG anticardiolipin antibodies (ACA) were determined by standardized enzyme-linked immunoassay.
RESULTS: Fifty-six patients were included. Only one patient (1.8%) had a titer of IgM ACA higher than 15 MPL units and no patient had a titer of IgG ACA higher than 15 GPL units. Six patients (10.7%) had low IgM ACA titers (4-15 MPL units) and 18 patients (32.1%) had low IgG ACA titers (4-15 GPL units). There were no differences in the frequencies of a low IgM or IgG ACA titer or in the means of IgM and IgG ACA titers in patients with complicated and uncomplicated DM, with and without cardiovascular disease, with and without nephropathy, or with and without retinopathy.
CONCLUSIONS: Moderate to high ACA titers must be exceptional in patients with type 2 DM. Low ACA titers may occur in patients with type 2 DM. These low titers do not seem to be associated with complicated DM, cardiovascular disease, nephropathy or retinopathy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19251581      PMCID: PMC2757429          DOI: 10.3121/cmr.2008.828

Source DB:  PubMed          Journal:  Clin Med Res        ISSN: 1539-4182


  10 in total

1.  Anticardiolipin antibody levels in diabetic subjects with and without coronary artery disease.

Authors:  T J Hendra; E Baguley; E N Harris; M H Khamashta; R C Trembath; G R Hughes; J S Yudkin
Journal:  Postgrad Med J       Date:  1989-03       Impact factor: 2.401

Review 2.  Antiphospholipid antibody testing: which are most useful for diagnosis?

Authors:  Maria Laura Bertolaccini; Graham R V Hughes
Journal:  Rheum Dis Clin North Am       Date:  2006-08       Impact factor: 2.670

3.  Autoantibodies: innocent bystander or key player in immunosenescence and atherosclerosis?

Authors:  Kimberly P Liang; Sherine E Gabriel
Journal:  J Rheumatol       Date:  2007-06       Impact factor: 4.666

4.  Qualitative and quantitative studies of autoantibodies to phospholipids in diabetes mellitus.

Authors:  P Gargiulo; J Goldberg; B Romani; R Schiaffini; P Ciampalini; W P Faulk; J A McIntyre
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

5.  Prevalence of antiphospholipid antibodies is not different in Chilean diabetic patients and normal individuals.

Authors:  Iván G Palomo; Verónica E Mujica; Marcelo L Alarcón; Jaime G Pereira; Marcela R Vásquez
Journal:  J Diabetes Complications       Date:  2005 May-Jun       Impact factor: 2.852

Review 6.  Diabetes mellitus: a hypercoagulable state.

Authors:  M E Carr
Journal:  J Diabetes Complications       Date:  2001 Jan-Feb       Impact factor: 2.852

7.  Anticardiolipin and anti-beta2 glycoprotein I antibody concentrations in patients with type 2 diabetes mellitus.

Authors:  Ilhan Tarkun; Abdullah Hacihanefioğlu; Pinar Tarkun; Berrin Cetinarslan; Zeynep Cantürk
Journal:  Diabetes Res Clin Pract       Date:  2005-06       Impact factor: 5.602

8.  Vascular complications of diabetes mellitus: what role for phospholipid-binding antibodies?

Authors:  F Galtier-Dereure; C Biron; M Vies; V Bourgeois; J F Schved; J Bringer
Journal:  Lupus       Date:  1998       Impact factor: 2.911

9.  A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection.

Authors:  J E Hunt; H P McNeil; G J Morgan; R M Crameri; S A Krilis
Journal:  Lupus       Date:  1992-02       Impact factor: 2.911

10.  Detection of anti-phospholipid (cardiolipin, phosphatidylserine) antibodies in the serum of patients with non insulin-dependent (type 2) diabetes mellitus and macroangiopathy. Coexistence of anti-platelet reactivity.

Authors:  G Triolo; E Giardina; G Scarantino; G Seddio; G Bompiani
Journal:  Diabetes Res       Date:  1989-02
  10 in total
  2 in total

1.  Upper extremity venous thrombosis associated with primary antiphospholipid syndrome and immunoglobulin M nephropathy in diabetes mellitus type II.

Authors:  Can Hüzmeli; Ferhan Candan; Ayşe Şeker Koçkara; Demet Alaygut; Mansur Kayataş
Journal:  Eur J Rheumatol       Date:  2015-06-24

2.  Diabetic muscle infarction: a systematic review.

Authors:  William B Horton; Jeremy S Taylor; Timothy J Ragland; Angela R Subauste
Journal:  BMJ Open Diabetes Res Care       Date:  2015-04-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.